Products
Pre-made Xentuzumab benchmark antibody ( Whole mAb, anti-IGF1;IGF2 therapeutic antibody, Anti-IGF/IGF-I/IGFI/MGF;C11orf43/GRDF/IGF-II/PP9974/SRS3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-634
Pre-Made Xentuzumab biosimilar, Whole mAb, Anti-IGF1;IGF2 Antibody: Anti-IGF/IGF-I/IGFI/MGF;C11orf43/GRDF/IGF-II/PP9974/SRS3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A humanized IgG1 insulin-like growth factor (IGF) monoclonal antibody targeting the IGF ligands 1 (IGF-1) and 2 (IGF-2), with potential antineoplastic activity. Upon administration, xentuzumab binds to both IGF-1 and IGF-2 and inhibits the binding of these ligands to their receptor, IGF-1R.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-634-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Xentuzumab biosimilar, Whole mAb, Anti-IGF1;IGF2 Antibody: Anti-IGF/IGF-I/IGFI/MGF;C11orf43/GRDF/IGF-II/PP9974/SRS3 therapeutic antibody |
| INN Name | Xentuzumab |
| Target | IGF1;IGF2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Boehringer Ingelheim;Eli Lilly |
| Conditions Approved | na |
| Conditions Active | Breast cancer;Prostate cancer |
| Conditions Discontinued | Non-small cell lung cancer;Solid tumours |
| Development Tech | MorphoSys HuCAL Phage Display |
